<br>        Inclusion Criteria:<br><br>          -  Have an Eastern Cooperative Oncology Group performance status of 0 or 1.<br><br>          -  Have a histologically or cytologically confirmed diagnosis of non-resectable,<br>             recurrent, or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic<br>             cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater) .<br><br>          -  Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).<br><br>          -  Have adequate biliary drainage.<br><br>          -  Have adequate organ function.<br><br>          -  Males and females are sterile, postmenopausal, or compliant with a highly effective<br>             contraceptive method.<br><br>          -  Female participants of childbearing potential must have a negative serum pregnancy<br>             test within 7 days prior to first dose.<br><br>          -  Are willing to provide blood/serum/plasma and tumor tissue samples for research<br>             purposes. Submission of blood/serum/plasma and tumor tissue samples is mandatory for<br>             participation in this study, unless restricted per local regulations.<br><br>        Exclusion Criteria:<br><br>          -  Previous systemic therapy for locally advanced or metastatic disease is not allowed.<br><br>          -  Have a history of or have current hepatic encephalopathy of any grade, or ascites of<br>             Grade >1, or cirrhosis with Child-Pugh Stage B or higher.<br><br>          -  Have ongoing or recent (=6 months) hepatorenal syndrome.<br><br>          -  Have had a major surgical procedure or significant traumatic injury including<br>             nonhealing wound, peptic ulcer, or bone fracture =28 days prior to randomization.<br><br>          -  Anticipate having a major surgical procedure during the course of the study.<br><br>          -  Has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord<br>             compression.<br><br>          -  Within 6 months prior to randomization, have had any arterial thrombotic event,<br>             including myocardial infarction, unstable angina, cerebrovascular accident, or<br>             transient ischemic attack.<br><br>          -  Have an uncontrolled arterial hypertension with systolic blood pressure =150 or<br>             diastolic blood pressure =90 millimeters of mercury (mm Hg) despite standard medical<br>             management.<br><br>          -  Have a previous malignancy within 5 years of study entry or a concurrent malignancy.<br><br>          -  Have a history of gastrointestinal perforation and/or fistulae within 6 months prior<br>             to randomization.<br><br>          -  Have a known allergy or hypersensitivity reaction to any of the treatment components.<br><br>          -  Have a history of uncontrolled hereditary or acquired thrombotic disorder.<br><br>          -  Have uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases<br>             or secondary effects of cancer that induce a high medical risk and/or make assessment<br>             of survival uncertain.<br><br>          -  Have mixed hepatocellular biliary tract cancer histology.<br><br>          -  Have a corrected QT interval >470 milliseconds as calculated be the Fredericia<br>             equation.<br>